SLC5A2 and chronic kidney disease: Another recent study summarized the effects of SGLT2 inhibitors across diverse populations (diabetes, HF, CKD, non-diabetic kidney disease), showing that they confer substantial reductions in cardiovascular death, HF hospitalizations, and kidney composite outcomes even in non-diabetic CKD.